Modella AI and AstraZeneca link for cancer clinical development
Modella AI has signed a multi-year agreement with AstraZeneca to expedite AI-driven oncology clinical development. The partnership will give AstraZeneca…
04 Jul 2025
AstraZeneca’s Imfinzi approved in Europe for muscle-invasive bladder cancer
AstraZeneca has added another indication to its blockbuster immunotherapy Imfinzi (durvalumab), gaining European approval to treat a type of bladder cancer. Imfinzi is now approved to treat adult patients with…
04 Jul 2025
Big pharma braces for revenue headwinds as patent expiries loom
One of the biggest patent cliffs is set to hit the pharmaceutical industry this decade, with major players bracing for a blow to their revenue streams, according to market analysis.…
04 Jul 2025
Biocon’s Denosumab biosimilars gain EU marketing authorisation
Biocon Biologics’ Denosumab biosimilars, Vevzuo and Evfraxy, have received marketing authorisation in the European Union (EU). This approval from the European Commission (EC) allows for their use in bone-related conditions…
04 Jul 2025
Brii Biosciences and Joincare sign licence agreement for BRII-693
Brii Biosciences and the Joincare Pharmaceutical Group have signed a licence and technology transfer agreement for BRII-693, a new synthetic lipopeptide being developed for multidrug and extensively drug-resistant (MDR/XDR) gram-negative…
03 Jul 2025
Theratechnologies shares surge 25% amid $254m Future Pak takeover
Contract manufacturer Future Pak will acquire Theratechnologies in a $254m deal, bringing an end to a drawn-out sale process of the Canadian HIV-specialist biopharma. Via its affiliate CB Biotechnology, US-headquartered…
03 Jul 2025
UK Government reveals 10-year plan for NHS
The UK’s Labour Government has revealed its ’10-Year Health Plan’ for the country’s National Health Service (NHS). Speaking at a community health centre in London, Health Secretary Wes Streeting outlined…